Emerging tissue-engineering and cell transplantation therapies have the potential to provide solutions to many of the treatment challenges facing neurologists today.
by Robert Neil
Emerging tissue-engineering and cell transplantation therapies have the potential to provide solutions to many of the treatment challenges facing neurologists...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.
